Sign up USA
Proactive Investors - Run By Investors For Investors

Callitas Health Inc has big plans for broad product portfolio

The health and wellbeing group, which has a broad product portfolio, had an eventful 2017,
Callitas Health Inc has big plans for broad product portfolio
ToConceive, the group's fertility enhancing product, has been launched in North America

Shares in Callitas Health Inc (CNSX:LILY) have had a good run of late, adding around 26% since the new year.

The health and wellbeing group, which boasts a number of products, had an eventful 2017, which included parent company M Pharma Inc, changing its name to Callitas Health Inc in  September, alongside a share consolidation.

In a wide-ranging letter to shareholders in the same month the group told investors: "Callitas has now advanced our mandate over the past 15 months by expanding and diversifying our treatment portfolio within our focus areas, adding significant revenue to the bottom line and attaining FDA pathway approval for our C-103 project, and pending for our Extrinsa product.

"Our team continues to grow with the restructuring of our Board of Directors in December and the addition of a COO, CFO, Director of Brand Management and now, Director of Sales and Marketing."

New interim boss..

And early this year chief operating officer James Thompson was named as interim president and chief executive after it emerged Gary Thompson was temporarily stepping down from the two roles due to ongoing health issues.

Thompson was previously the managing member at 40 J’s LLC, the private healthcare development group whose primary assets were acquired in early 2017 by Callitas.

Efforts in 2018 have so far largely focused on growth and potential of the product portfolio.

Last month, it hired Freyeur & Trogue (F&T) to provide development consulting to help optimise its product portfolio development and commercialization.

It also said renowned sex and relationship researcher and therapist Dr Laura Berman had joined the firm as chief health advisor.

Making progress with Extrinsa

And notably, late last year, Callitas received a successful response from the US FDA on its pre-investigational new drug (IND) application for its Extrinsa topical gel to treat female sexual dysfunction (FSD), causing it to talk about potential plans to kick off clinical trials in the first quarter of 2018.

The firm has said previously it reckons this (Extrinsa) could be a US$1bn opportunity; Addyi, the only drug currently approved for the treatment of female sexual desire disorder was purchased by Valeant Pharmaceuticals (NYSE:VRX) from Sprout for more than US$1bn in 2016.

Valeant had estimated that sales would ramp up to US$1bn annually for this drug, and it makes no claims to treat orgasm disorders, so the potential market for Extrinsa should be higher.

Elsewhere, ToConceive is the group's fertility enhancing product launched in North America, for which the group has high hopes.

It's FDA cleared and clinically proven to increase a woman’s own natural conception lubrication, called transudate.

C - 103 is the reformulated weight loss treatment, which was Orlistat (which had unwelcome side effects)  and the firm has targeted US$500mln in the US market alone as first year revenues, once it is approved by the FDA.

The firm's partner on the treatment is Camargo Pharmaceutical Services and the aim is to launch Phase II dose finding studies, solidify the chemistry and plan the non-clinical testing required by the FDA.

"Business plan development is complete and partnership discussions are underway to drive pivotal clinical trials for this promising new weight loss drug formulation," the group said late last year.

In November, the group said it had pending patenting status from the US patent office concerning the technology concerning cannabinoids branded as CannaMint Strips by Callitas.

"The direct distribution of cannabinoids does not fit into our Callitas business model, but licensing this technology to manufacturers  and distributors in North America advances our goal of improving health and wellness," said Thompson.

So with a broad portfolio and high hopes, there is much to potentially look forward to from Callitas this year.

Shares are up 6.45% to C$0.33.

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

syringe
June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use